SarahElizabethYentzMD

PubMed

• 1 citations
  A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.
  Irene Tsung, Edward Green, Phillip Palmbos, Zachery Sloan, Zachery R Reichert, Ulka Vaishampayan, David C Smith, Megan E V Caram, Sarah Yentz, Stephanie Daignault-Newt...> ;The Journal of Urology. 2023 Jan 1
• 12 citations
  Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer.
  Alex K Bryant, Kamya Sankar, Garth W Strohbehn, Lili Zhao, David Elliott, Angel Qin, Sarah Yentz, Nithya Ramnath, Michael D Green> ;Lung Cancer. 2022 Jan 1
• 2 citations
  Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma.
  Morgan Homan, Govind Warrier, Christopher D Lao, Sarah Yentz, Shawna Kraft, Leslie A Fecher> ;Frontiers in Oncology. 2022 Jan 1
• 11 citations
  Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
  Francesco Giovinazzo, Fiammetta Soggiu, Jin-Young Jang, Eva Versteijne, Geertjan van Tienhoven, Casper H.J. van Eijck, Youngmin Han, Seong Ho Choi, Chang Moo Kang, Mar...> ;Frontiers in Oncology. 2020 Aug 11
• 7 citations
  Implementation of a Multidisciplinary Care Pathway via an Emergency Department-ICU to Improve Care of Emergency Department Patients Presenting With Leukostasis.
  Nathan L. Haas, Abhinav Nafday, James A. Cranford, Sarah Yentz, Dale L. Bixby, Benjamin S. Bassin> ;Critical Care Explorations. 2020 Feb 24
• 22 citations
  Immunotherapy for mucosal melanoma.
  Sarah Yentz, Christopher D. Lao> ;Annals of Translational Medicine. 2019 Jun 13
• Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.
  Tan, M. H.,Iyengar, R.,Mizokami-Stout, K.,Yentz, S.,MacEachern, M. P.,Shen, L. Y.,Redman, B.,Gianchandani, R.> ;Clin Diabetes Endocrinol. 2019 Jan 30
• Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
  Yentz, S.,Smith, D.> ;BioDrugs. 2018 Jul 08
• 37 citations
  Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer
  Ajjai Alva, Luke Nordquist, Stephanie Daignault, Saby George, Jorge Ramos, Costantine Albany, Sudhir Isharwal, Matthew McDonald, Gregory Campbell, Pongwut Danchaivijit...> ;The Prostate. 2017 Apr 1
• 3 citations
  Eyelid Metastasis in Non-Small Cell Lung Cancer: Diagnosis and Management.
  Shannon S. Joseph, Sarah Yentz, Shravani Mikkilineni, Christine C. Nelson, Gregory P. Kalemkerian> ;The American Journal of Medicine. 2016 Sep 1
• 9 citations
  Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.
  Gentzler, R. D., Yentz, S. E., Patel, J. D.> ;Current treatment options in oncology. 2013 Aug 31
• The impact of tobacco cessation training of medical students on their attitude towards smoking.
  Yentz, S., Klein, R. J., Oliverio, A. L., Andrijasevic, L., Likic, R., Kelava, I., Kokic, M.> ;Med Teach. 2012
• Molecular imaging for guiding oncologic prognosis and therapy in esophageal adenocarcinoma.
  Yentz, S., Wang, T. D.> ;Hosp Pract (Minneap). 2011 Apr
• Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis.
  Yentz, S.,Onwuemene, O. A.,Stein, B. L.,Cull, E. H.,McMahon, B.> ;Thrombosis. 2015 Nov 07
• Join now to see all

Journal Articles

• Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy  
  David Smith, Sarah Yentz, Biodrugs